HAS2 and urinary bladder cancer: These experiments show that loss of HA synthesis by genetic alteration (inhibition of HAS2 expression) or by an inhibitor (4MU) or addition of superfluous HA have little effect on CD44 and RHAMM expression in UMUC3 and T24T bladder cancer cells.